The larger studies examining the effects of FcgR polymorphisms on the outcome of follicular lymphoma and CLL patients treated with rituximab combined with chemotherapy showed no association between FcgR genotype and either response rate or outcome [26,33]. The gene discussed is FCGR2A; the disease is B-cell chronic lymphocytic leukemia.